This Day That Year


sqzbiotech oct29 Shares of SQZ Biotechnologies Co. (SQZ) have lost more than 50% year-to-date and trade around $13. The company's lead cancer vaccine candidate SQZ-PBMC-HPV is being studied in a phase I/II trial in HLA-A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors, dubbed SQZ-PBMC-HPV-101.

taysha sep23 Taysha Gene Therapies Inc. (TSHA), a pivotal-stage gene therapy company, has a couple of clinical, regulatory and preclinical milestones lined up for the remainder of this year. The company has 26 AAV-based gene therapies under development for the treatment of monogenic diseases of the central nervous system...

inhibrx 081921 Shares of Inhibrx Inc. (INBX) have lost more than 40% of their value from their all-time high of $50.97, recorded last December, and trade around $29.

Follow RTT